Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial

Maria E. Goossens, Maurice P. Zeegers, Hendrik van Poppel, Steven Joniau, Koen Ackaert, Filip Ameye, Ignace Billiet, Johan Braeckman, Alex Breugelmans, Jochen Darras, Kurt Dilen, Lieven Goeman, Bertrand Tombal, Siska Van Bruwaene, Ben Van Cleyenbreugel, Frank Van der Aa, Kris Vekemans, Frank Buntinx

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)9-18
JournalEuropean Journal of Cancer
Volume69
DOIs
Publication statusPublished - Dec 2016

Keywords

  • Selenium
  • Bladder cancer
  • Non-invasive urothelial carcinoma
  • Transitional cell carcinoma
  • Chemoprevention
  • Randomised clinical trial
  • Urology

Cite this

Goossens, M. E., Zeegers, M. P., van Poppel, H., Joniau, S., Ackaert, K., Ameye, F., Billiet, I., Braeckman, J., Breugelmans, A., Darras, J., Dilen, K., Goeman, L., Tombal, B., Van Bruwaene, S., Van Cleyenbreugel, B., Van der Aa, F., Vekemans, K., & Buntinx, F. (2016). Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. European Journal of Cancer, 69, 9-18. https://doi.org/10.1016/j.ejca.2016.09.021